Prediction Case File
YouTubeEvaluation Complete

Friends! In this video, I'm going to do an Intel stock analysis & discuss the risks and upside potential of INTC stock

1 extracted signal · 1 resolved · 0 still active

The Patient Investor profile imageThe Patient InvestorIndependent analyst profile
Source published
23 Jan 2026, 19:33 UTC
Recorded by Tahlil Plus
18 May 2026, 20:23 UTC
Video preview for Friends! In this video, I'm going to do an Intel stock analysis & discuss the risks and upside potential of INTC stock
Source overview

AI-generated source summary

Intel reported earnings per share of 15 cents (adjusted) against 8 cents expected and revenue of $13.7 billion versus $13.4 billion expected, indicating a beat on both metrics. However, the company's Q1 guidance for 2026 was significantly below expectations, causing the stock to drop 11% in after-hours trading to $48.26. The computer chip segment revenue declined quarter-over-quarter, but the AI chip segment showed reacceleration and operating margin expansion (from 23% to 26%). The Intel Foundry business remains unprofitable with negative 55.7% operating margins but is seen as a national security investment to bring chip manufacturing to the US. Intel recently sold $5.0 billion of common stock to NVIDIA to fund capital expenditures for scaling the foundry, which has led to diluted shares outstanding. Despite current valuation metrics appearing high (126x depressed earnings), the company is expected to become profitable, with EPS projected to reach $1.97 by 2028. Based on a 25x earnings multiple on 2028 EPS, a long-term target of $71 is calculated for 2030. The analyst, however, believes Intel is currently overvalued and would only consider buying at $35.50 per share to achieve a potential double.

AI-generated summary based on the source content.

Live evaluation

Signal outcomes at a glance

Evaluation Complete
Signals
1
Extracted from this source
Open
0
Still being tracked
Successful
1
Resolved successfully
Failed
0
Resolved unsuccessfully
Other
0
Cancelled, invalid or excluded
Resolved success
100%
1 resolved; open signals omitted
Extracted intelligence

Signals in this source

Case timeline

Evidence and evaluation progress

  1. Original source published

    The analyst published the original source item.

  2. Source recorded by Tahlil Plus

    The public source was preserved as the evidence record for this case.

  3. Market predictions extracted

    1 eligible signal linked to this case.

  4. Outcome tracking started

    Tahlil Plus began monitoring the extracted predictions.

  5. First prediction resolved

    The first evaluable outcome in this case reached a terminal result.

  6. Case evaluation completed

    All evaluable predictions in this case reached terminal outcomes.

Analyst snapshot

The Patient Investor

Platform-wide history, separate from this source evaluation.

Reliability
47.9
Tracked signals
355
Historical success
34.9%
View full analyst profile →
Methodology & disclosure

Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.

Continue the evidence trail